Latest Articles
Sexual shame is an unspoken truth of endometriosis - but it shouldn't be - Cosmopolitan UK
Sexual shame is an unspoken truth of endometriosis - but it shouldn't be Cosmopolitan UK
Published: June 23, 2024, 7 a.m.
The Targeted Pulse: Endometrial Cancer Scores Multiple FDA Approvals, T-DXd Shows Promise in Breast Cancer, and More - Targeted Oncology
The Targeted Pulse: Endometrial Cancer Scores Multiple FDA Approvals, T-DXd Shows Promise in Breast Cancer, and More Targeted Oncology
Published: June 23, 2024, 7 a.m.
National Grid fund offering job-seekers financial support - BBC.com
National Grid fund offering job-seekers financial support BBC.com
Published: June 23, 2024, 7 a.m.
Out-of-action Bedford Hospital lifts lead to cancellations - BBC.com
Out-of-action Bedford Hospital lifts lead to cancellations BBC.com
Published: June 23, 2024, 7 a.m.
The association between endometrial polyps and insulin resistance from the expression of PI3K and AKT proteins perspective - BioMed Central
The association between endometrial polyps and insulin resistance from the expression of PI3K and AKT proteins perspective BioMed Central
Published: June 22, 2024, 7 a.m.
Gloucester trains delayed after police incident - BBC.com
Gloucester trains delayed after police incident BBC.com
Published: June 22, 2024, 7 a.m.
New Hebron woman welcomes birth of triplets - Dailyleader
New Hebron woman welcomes birth of triplets Dailyleader
Published: June 22, 2024, 7 a.m.
Lenvatinib/Pembrolizumab Misses OS End Points, But Still Shows Activity, in Advanced Endometrial Cancer - OncLive
Lenvatinib/Pembrolizumab Misses OS End Points, But Still Shows Activity, in Advanced Endometrial Cancer OncLive
Published: June 21, 2024, 7 a.m.
FDA Approves KEYTRUDA + Chemo for Primary Advanced, Recurrent Endometrial Carcinoma - HealthDay
FDA Approves KEYTRUDA + Chemo for Primary Advanced, Recurrent Endometrial Carcinoma HealthDay
Published: June 21, 2024, 7 a.m.
Frontline Durvalumab/Chemo, Then Maintenance Durvalumab ± Olaparib, Improves ORR in Endometrial Cancer - OncLive
Frontline Durvalumab/Chemo, Then Maintenance Durvalumab ± Olaparib, Improves ORR in Endometrial Cancer OncLive
Published: June 21, 2024, 7 a.m.
Link copied to clipboard!